Wellington Management Group
URGN icon

Wellington Management Group’s UroGen Pharma URGN Stock Holding History

Wellington Management Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.25M Buy
115,362
+15,147
+15% +$410K ﹤0.01% 1478
2026
Q1 		$1.8M Sell
100,215
-25,819
-20% -$518K ﹤0.01% 1573
2025
Q4 		$2.95M Buy
126,034
+736
+0.6% +$16K ﹤0.01% 1515
2025
Q3 		$2.5M Sell
125,298
-32,754
-21% -$588K ﹤0.01% 1579
2025
Q2 		$2.17M Buy
158,052
+9,974
+7% +$95.7K ﹤0.01% 1562
2025
Q1 		$1.64M Buy
148,078
+1,125
+0.8% +$12K ﹤0.01% 1599
2024
Q4 		$1.57M Buy
146,953
+9,653
+7% +$116K ﹤0.01% 1632
2024
Q3 		$1.74M Sell
137,300
-18,778
-12% -$279K ﹤0.01% 1576
2024
Q2 		$2.62M Buy
156,078
+19,337
+14% +$275K ﹤0.01% 1460
2024
Q1 		$2.05M Buy
136,741
+32,141
+31% +$525K ﹤0.01% 1516
2023
Q4 		$1.57M Buy
104,600
+34,537
+49% +$448K ﹤0.01% 1533
2023
Q3 		$982K Buy
+70,063
New +$1.12M ﹤0.01% 1614
2022
Q1 		– Sell
-238,008
Closed -$2.26M – 2228
2021
Q4 		$2.26M Sell
238,008
-79,292
-25% -$1.12M ﹤0.01% 1636
2021
Q3 		$5.34M Sell
317,300
-1,072,325
-77% -$17M ﹤0.01% 1495
2021
Q2 		$21.2M Sell
1,389,625
-264,958
-16% -$4.79M ﹤0.01% 1085
2021
Q1 		$32.2M Sell
1,654,583
-186,054
-10% -$3.95M 0.01% 940
2020
Q4 		$33.2M Sell
1,840,637
-155,353
-8% -$3.25M 0.01% 900
2020
Q3 		$38.5M Sell
1,995,990
-5,602
-0.3% -$127K 0.01% 768
2020
Q2 		$52.3M Buy
2,001,592
+906,207
+83% +$22.1M 0.01% 691
2020
Q1 		$19.5M Sell
1,095,385
-126,012
-10% -$3.4M 0.01% 880
2019
Q4 		$40.8M Sell
1,221,397
-95,869
-7% -$2.62M 0.01% 814
2019
Q3 		$31.4M Sell
1,317,266
-99,906
-7% -$3.27M 0.01% 848
2019
Q2 		$50.9M Sell
1,417,172
-35,065
-2% -$1.29M 0.01% 751
2019
Q1 		$53.6M Buy
1,452,237
+479,083
+49% +$20.1M 0.01% 715
2018
Q4 		$41.9M Sell
973,154
-20,632
-2% -$928K 0.01% 763
2018
Q3 		$46.9M Buy
993,786
+7,126
+0.7% +$331K 0.01% 822
2018
Q2 		$49.1M Buy
986,660
+46,785
+5% +$2.72M 0.01% 799
2018
Q1 		$46.7M Buy
939,875
+420,785
+81% +$21.1M 0.01% 806
2017
Q4 		$19.3M Buy
519,090
+229,828
+79% +$8.18M ﹤0.01% 1079
2017
Q3 		$9.12M Sell
289,262
-463,478
-62% -$10.2M ﹤0.01% 1291
2017
Q2 		$13.6M Buy
+752,740
New +$13.1M ﹤0.01% 1132

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Wellington Management Group's URGN Position: Q2 2026 in Review

Wellington Management Group increased its UroGen Pharma (URGN) stake by 15% in Q2 2026, buying an estimated $410K and bringing the position to 115,362 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Wellington Management Group first reported a position in URGN in Q2 2017 and has held it in 31 quarters since. The position peaked at $53.6M in Q1 2019. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Wellington Management Group held 115,362 shares of UroGen Pharma worth $4.25M as of Q2 2026.
  • Wellington Management Group bought 15,147 UroGen Pharma shares in Q2 2026, an estimated $410K.
  • UroGen Pharma made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1478 holding.
  • Wellington Management Group first reported a position in UroGen Pharma in Q2 2017 and has held it in 31 quarters since.
  • Wellington Management Group's UroGen Pharma position peaked at $53.6M in Q1 2019.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.